IMAC Stock Price Increases 23.97%: Why It Happened – Pulse 2.0

The stock price of IMAC Holdings Inc (NASDAQ: IMAC) a company that provides orthopedic therapies through a chain of innovative medical advancements and care regeneration centers in the US has increased by 23.53% as it went from a previous close of $1.19 to $1.47. One of the biggest triggers for why the stock price increased is due to an announcement by the company that it completed a first infusion of stem cells in clinical study for the treatment of bradykinesia due to Parkinsons disease

Read more
In COVID-19 Clinical Trials, Experts from Baptist Health’s Cancer Institutes Treat Patients With Mild or Severe Symptoms – Baptist Health South…

Offering more hope to patients with COVID-19, cancer experts throughout Baptist Health South Florida are launching new clinical trials. The trials, developed as a result of promising initial emergency and experimental COVID-19 therapies at Miami Cancer Institute on the Baptist Hospital campus in Miami and at the Eugene M.

Read more
Stem Cell Exosomes Market 2020-28 steering forces heading towards impressive growth with Anjarium Biosciences, Codiak Biosciences, Capricor…

Exosomes are nano-sized vesicles containing biological signaling molecules that mediate cellcell signaling. Mesenchymal stem cells (MSCs) are believed to have antitumor effects and are preferred for their properties, such as immune-modulating capacity and ability to accumulate at the tumor site.

Read more
How Mesenchymal Stem Cells Work | Colorado Medical Solutions

Stem Cell Therapy Background Regenerative medicine utilizes the bodys own stem cells in order to stimulate healing and repair of damaged tissues and organs. According to the American Association of Blood Banks (AABB), which advances transfusion and cellular therapies worldwide, current estimates indicate that approximately 1 in 3 Americans may benefit from regenerative medicine

Read more
Hadassah Medical Center and Neurogenesis Announce Groundbreaking Results from a Phase 2 Study in Progressive Multiple Sclerosis treated with NG-01…

JERUSALEM, Dec. 8, 2020 /PRNewswire/ --NeuroGenesis, a clinical-stage biopharmaceutical company advancing innovative cell therapies to combat myelin-related neurodegenerative diseases, and Hadassah Medical Center announced today highly positive results from a placebo-controlled Phase 2 clinical trial, headed by Prof. Dimitrios Karussis, together with Dr.

Read more
Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz Cellular…

PHOENIX, Dec. 10, 2020 /PRNewswire/ --Creative Medical Technology Holdings trading under the ticker symbol CELZ announced today its patent filing based on data covering utilization of the Company's ImmCelz product at generating what is termed in the field of immunology as "infectious tolerance." Using an animal model of rheumatoid arthritis, investigators demonstrated administration of ImmCel protected mice from immunologically mediated joint damage. Importantly, cells from treated mice were able to reverse disease when transferred to arthritic mice

Read more